Mission Biocapital
SEC exempt reporting adviser (venture capital exemption).
- HQ
- MA
Mission BioCapital provides early-stage capital to life science entrepreneurs and offers a platform for them to realize their visions. Its team includes partners and general partners based in San Francisco and Cambridge, along with a Chief Financial Officer. Its portfolio companies include Bolt Threads, Sound Agriculture, Wildtype, Vaxess Technologies, Mammoth Biosciences, and Magnap.
New fund likely raising soon
The firm's newest fund is 4 to 7 years past its first sale and no newer Form D has been filed.
01 · Says / Does
| Tag | Says | Does | Historically (to 2020) |
|---|---|---|---|
| Stages | Not stated | Not enough dated deals | Series A |
| Sectors | Biotech | Not enough dated deals | Biotech, Healthtech |
| Regions | Global | Not enough dated deals | MA |
Says: what the firm's funds state. Does: from 0 dated deals in the last 24 months.
Historical focus (through 2020), derived from historical deal data.
| Year | Deals | Top sectors |
|---|---|---|
| 2018 | 3 | Biotech, Healthtech, Advanced materials |
| 2019 | 4 | Biotech, Healthtech, Digital health |
| 2020 | 2 | Biotech, Healthtech, Digital health |
Stage mix over time
- Pre-seed
- Seed
- Series A
- Series B
- Growth
| Year | Pre-seed | Seed | Series A | Series B | Growth |
|---|---|---|---|---|---|
| 2018 | 0 | 1 | 2 | 0 | 0 |
| 2019 | 0 | 0 | 4 | 0 | 0 |
| 2020 | 0 | 0 | 1 | 1 | 0 |
| 2021 | 0 | 0 | 0 | 0 | 0 |
| 2022 | 0 | 0 | 0 | 0 | 0 |
| 2023 | 0 | 0 | 0 | 0 | 0 |
| 2024 | 0 | 0 | 0 | 0 | 0 |
| 2025 | 0 | 0 | 0 | 0 | 0 |
| 2026 | 0 | 0 | 0 | 0 | 0 |
02 · Fund history
| Fund | Year | Size | Status |
|---|---|---|---|
| MISSION BIOCAPITAL V LP | 2020 | $191.93M to $259.31M (Form D and SEC adviser filing) | Follow-ons only |
03 · People across funds
- Cassidy Blundell, PhD, Partner
MISSION BIOCAPITAL V LP (Team)
- Johannes Fruehauf, MD PhD, General Partner
MISSION BIOCAPITAL V LP (Team)
- Loretta McClary, Chief Financial Officer
MISSION BIOCAPITAL V LP (Team)
- Peter Parker, Managing General Partner
MISSION BIOCAPITAL V LP (Team)
- Robert Blazej, PhD, Partner
MISSION BIOCAPITAL V LP (Team)
- Steve Tregay, PhD, Managing General Partner
MISSION BIOCAPITAL V LP (Team)
- Ulrik B. Nielsen, General Partner
MISSION BIOCAPITAL V LP (Team)
- Zach Collins, PhD, Partner
MISSION BIOCAPITAL V LP (Team)
- Chaya D. Patel, PhD, Principal
On the team page, not linked to a fund
- Chris Carlin, Chief Operations Officer and Chief Compliance Officer
On the team page, not linked to a fund
- Clay Rowland, Investment Associate
On the team page, not linked to a fund
- Doug Crawford, PhD, Managing General Partner, San Francisco
On the team page, not linked to a fund
- Jennifer Griffin, PhD, Partner
On the team page, not linked to a fund
- Josephine J. Brysting, PhD, Investment Analyst, Copenhagen
On the team page, not linked to a fund
- Linda Eng, Director of Operations, Bay Area
On the team page, not linked to a fund
- Mark Byrnes, Director of Operations, Cambridge
On the team page, not linked to a fund
- Michael D. Taylor, PhD, Operating Partner
On the team page, not linked to a fund
- Nana Kusi Minkah, Accounting and Operations Associate
On the team page, not linked to a fund
- Samar Jahan, Vice President of Finance
On the team page, not linked to a fund
- Sarika Temme-Bapat, Venture Operations Associate
On the team page, not linked to a fund
- Ulrik B. Nielsen, Ph.D., General Partner
On the team page, not linked to a fund
04 · Recent deals
No dated deals found yet.
05 · Latest from the firm
No news from the firm's website yet.
06 · Sources
- https://www.missionbiocapital.com
- https://www.missionbiocapital.com/contact/
- https://www.missionbiocapital.com/team/
- https://www.missionbiocapital.com/portfolio/
- https://www.missionbiocapital.com/
Fund dates and sizes are from SEC Form D filings.
Last verified: Oct 25, 2026